Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

NASDAQ:BPTH opened at $0.81 on Friday. The company’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.59. Bio-Path has a one year low of $0.80 and a one year high of $12.40.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same quarter in the previous year, the firm earned ($10.60) EPS. On average, equities research analysts anticipate that Bio-Path will post -6.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is owned by hedge funds and other institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.